Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1 | Zendy

Teresa Di Desidero | Zendy; Anna Fioravanti | Zendy; Paola Orlandi | Zendy; Bastianina Canu | Zendy; Riccardo Giannini | Zendy; Nicla Borrelli | Zendy; Shan Man | Zendy; Ping Xu | Zendy; Gabriella Fontanini | Zendy; Fulvio Basolo | Zendy; Robert S. Kerbel | Zendy; Giulio Francia | Zendy; Romano Danesi | Zendy; Guido Bocci | Zendy

Open Access

Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1

Author(s) -

Teresa Di Desidero,

Anna Fioravanti,

Paola Orlandi,

Bastianina Canu,

Riccardo Giannini,

Nicla Borrelli,

Shan Man,

Ping Xu,

Gabriella Fontanini,

Fulvio Basolo,

Robert S. Kerbel,

Giulio Francia,

Romano Danesi,

Guido Bocci

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2013-1364

Subject(s) - sunitinib , anaplastic thyroid cancer , cancer research , cyclin d1 , vascular endothelial growth factor , protein kinase b , angiogenesis , vascular endothelial growth factor a , tyrosine kinase inhibitor , medicine , endocrinology , biology , pharmacology , phosphorylation , thyroid cancer , cancer , cell cycle , microbiology and biotechnology , vegf receptors

Recent experimental evidence suggests a rationale for the use of multitarget tyrosine kinase inhibitors for the treatment of thyroid cancers. Sunitinib showed promising preliminary results against anaplastic thyroid cancer (ATC), and it has been used for some patients who are ineligible for clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research